NEWARK, Calif., Dec. 4, 2017 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the company's President
and Chief Executive Officer, will participate in an analyst-led
fireside chat, to be held at 8 am ET
on December 14 at the BMO Capital
Markets 2017 Prescriptions for Success Healthcare Conference. The
BMO Capital Markets conference is taking place at the Westin Grand
Central Hotel in New York, NY.
A live and archived audio webcast of the presentation can be
accessed by visiting the Investors page of Protagonist Therapeutics
corporate website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics
Protagonist
Therapeutics is a clinical development-stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to address significant unmet
medical needs. Its primary focus is on developing potential
first-in-class oral targeted therapy-based peptide drugs that work
by blocking biological pathways that are currently targeted by
marketed injectable antibody drugs. Lead oral peptide candidates,
PTG-100 and PTG-200, are based on this approach. The alfa-4-beta-7
integrin antagonist PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe
ulcerative colitis, and the company's interleukin-23 receptor
antagonist PTG-200 is currently being studied in a Phase 1 clinical
trial in healthy volunteers in support of its development as a
potential treatment for Crohn's disease. The company recently
entered into a worldwide license and collaboration agreement with
Janssen Biotech for the clinical development of PTG-200.
Protagonist has also applied its platform to other disease areas
and is developing an injectable hepcidin mimetic, PTG-300, for the
treatment of rare diseases such as beta-thalassemia and
myelodysplastic syndromes (MDS). PTG-300 is currently being studied
in a Phase 1 clinical trial.
Protagonist is headquartered in Newark, California with pre-clinical and
clinical staff in California, and
discovery operations both in California and Brisbane, Queensland, Australia. For further
information, please visit http://www.protagonist-inc.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference-300565700.html
SOURCE Protagonist Therapeutics, Inc.